Access TOC
Download Data
December 2024
The global induced pluripotent stem cells production market size is calculated at US$ 1.66 in 2024, grew to US$ 1.82 billion in 2025, and is projected to reach around US$ 4.11 billion by 2034. The market is expanding at a CAGR of 9.47% between 2024 and 2034. iPSC holds great potential in developing therapeutics for various diseases and hence is in high demand.
Unlock Infinite Advantages: Subscribe to Annual Membership
Reprogrammed cells, known as induced pluripotent stem cells (iPSCs), have the amazing ability to proliferate and differentiate into a wide variety of cell types indefinitely. Clinical-grade iPSC lines are being actively developed by businesses all over the world to meet the demands of precision medicine, immunotherapies, and regenerative medicine.
Research on stem cells has advanced significantly, especially in the area of induced pluripotent stem cell (iPSC) technology. Refinement of iPSC categorization, cell function monitoring, and genetic analysis have all benefited greatly from the integration of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL). These improvements are expanding the use of iPSC technology in regenerative medicine, drug screening, and disease modeling.
Cancer therapy development
Rapid translational research, fueled by the increased availability of appropriate cancer models, is necessary to address the high mortality epidemic caused by the rising worldwide cancer burden. Numerous techniques for causing genetic and epigenetic alterations in cells that might promote malignant transformation have validated the promise of iPSC technology in cancer models. These models are useful for researching the beginning of cancer as well as altered pathways linked to its development and metastasis. Furthermore, iPSC-derived cancer avatars can be used to identify and validate therapeutic targets for the development of anticancer drugs by revealing disease dependencies.
Difficult to culture
Propagation and culture of human iPSCs are time-consuming procedures that require cautious handling. High-quality hiPSCs are necessary for downstream applications. HiPSC preservation and characterization need essentially different methods, techniques, and knowledge than immortalized cell lines. It can be challenging for both novice and sometimes experienced lab staff to successfully cultivate these cells and maintain their exceptional quality.
Personalized medicine
The potential of iPSC technology for disease models, regenerative therapies, and customized medicine is enormous, and it gives optimism for a time when patient-specific treatments will be standard. The creation of pluripotent cells via chemical induction allows researchers to get around moral dilemmas and provide customized treatments for a variety of illnesses.
By process, the manual iPSC production process segment held the largest share of the induced pluripotent stem cells production market in 2023. The manual procedure might be used to produce enough cells for targeted cell-based therapeutic applications on a modest scale, including phase I and II clinical trials or the initial stages of commercialization.
By process, the automated iPSC production process segment is expected to achieve the fastest CAGR in the induced pluripotent stem cells production market during the forecast period. Automated technologies are now being developed to meet the diverse requirements of hiPSC production. The beginning of iPSC-using research should be made simpler by automated culture equipment for cell processing. Numerous businesses produce automated platforms. These include Class II biosafety cabinets to guarantee sterile conditions for handling cells, robotic arms for handling liquids and labware, and incubators that offer exact temperature, CO2, and O2 control.
By workflow, the cell culture segment dominated the induced pluripotent stem cells production market in 2023. Long-term maintenance of a consistent cultured cell quality is desirable in the creation of an iPS cell mass manufacturing system. At every stage, stem cell cultivation relies on manual procedures carried out by knowledgeable professionals. However, mechanized culture methods make it possible to produce cells on a massive scale. An automated culture system increases the repeatability of cell cultures while also saving researchers time and effort.
By workflow, the cell characterization/analysis segment is estimated to grow at the fastest rate in the induced pluripotent stem cells production market during the predicted timeframe. Control and monitoring of the identification, purity, safety, and possible use of the starting materials, iPSC itself, need the development of the appropriate set of release and characterization tests. Depending on the target cell treatment indication and the factory or laboratory, several tests are employed for comprehensive characterization.
By product, the consumables & kits segment held the major share of the induced pluripotent stem cells production market in 2023. Kits and reagents contain various products needed for the growth of iPSC. These products come in kits, which consist of all the resources in a single kit, while reagents are sold separately in bulk.
By product, the automated platforms segment is anticipated to grow at the fastest rate in the induced pluripotent stem cells production market during 2024-2034. Research labs and commercial pharmaceutical testing may now more easily access this technology because of the introduction of repeatable end-to-end automated procedures for iPSC culture and differentiation that have been shown on commercially accessible platforms. Automated cell culture procedures provide several advantages, such as increased experimental scale, lower labor costs, and improved accuracy and reproducibility.
By application, the drug development & discovery segment was dominant in the induced pluripotent stem cells production market in 2023. Human pluripotent stem cells, or hiPSCs, provide special chances to find and create novel medications. They are a cheap, renewable supply of tissue-specific cell types that can forecast human reactions to new chemicals because of their capacity to develop into almost any form of cell.
By application, the regenerative medicine segment is assumed to grow at the fastest growth rate in the induced pluripotent stem cells production market during the forecast period. Scientists in regenerative medicine employ stem cells to investigate illnesses, test medications in labs without using humans or animals, and, in rare instances, treat patients. Researchers studying regenerative medicine now have a readily available and regenerative supply of stem cells to employ in their research on human development, the start of illness, and possible treatments.
By end-use, the biotechnology & pharmaceutical companies segment captured the largest share of the induced pluripotent stem cells production market in 2023. Induced pluripotent stem cells (iPSCs) are a promising therapeutic tool for treating a variety of disorders and have completely changed the area of biomedical research. Many businesses have realized the promise of iPSCs and are already selling cell types produced from hiPSCs for medication effectiveness screens, toxicity testing, and predictive safety pharmacology.
By end-use, the research & academic institutes segment is estimated to register the fastest CAGR in the induced pluripotent stem cells production market during the time frame of 2024-2034. Scientists investigate stem cells to see if these fundamental components of life might lead to the development of novel therapeutic interventions. They can also provide insight into the causes of specific illnesses and ailments. Additionally, scientists are investigating how specific stem cells might assist pharmaceutical companies in evaluating the efficacy and safety of drugs.
North America dominated the induced pluripotent stem cells production market in 2023. It has substantial investments in biomedical research, a strong healthcare infrastructure, and a huge number of important market participants. Furthermore, iPSC research and commercialization are supported by government initiatives and favorable regulatory laws. Furthermore, the area is the largest market for iPSCs because of its strong emphasis on personalized medicine and cutting-edge technology, which encourage the use of iPSC-based applications in disease modeling, regenerative medicine, and drug development.
For instance,
Asia Pacific is estimated to host the fastest-growing induced pluripotent stem cells production market during the forecast period because of a number of things. These include expanding research and development efforts, a rise in the prevalence of chronic illnesses, and increased spending on healthcare infrastructure. Innovation and the uptake of iPSC-based solutions are also fueled by growing partnerships between government, business, and academia. Asia Pacific has tremendous development potential in the iPSCs market due to its sizable and aging population, growing healthcare costs, and need for cutting-edge diagnostics and treatments. Furthermore, India's induced pluripotent stem cell market grew at the highest rate in the Asia-Pacific area, while China's market share was the greatest.
In January 2024, opening the CDMO business is a strategic decision that we anticipate will increase sales and cash flow by using our proven technology and production facility, according to Pluri's CEO and President, Yaky Yanay. PluriCDMOTM will assist forward-thinking businesses in creating and producing transformative treatments in the quickly expanding $5.2 billion cell and gene therapy market.
By Process
By Workflow
By Product
By Application
By End-use
By Region
December 2024
December 2024
November 2024
November 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts